Hereditary ATTR

According to a global registry study, late-onset inherited transthyretin amyloidosis was more likely to be misdiagnosed and to present with more heterogeneous and severe symptoms compared with early-onset disease. Read More ›

Recognizing critical differences in genotype and phenotype among patients with transthyretin amyloidosis or other inherited cardiovascular diseases is imperative for optimal outcomes. Read More ›

Providers face challenges with clinical vigilance and treatment for transthyretin amyloidosis due to the range of disease severity and phenotypic penetrance of carriers of variant forms. Read More ›

This study underscores the importance of assessing patients with transthyretin amyloidosis cardiomyopathy and carriers of the V122I mutation for peripheral polyneuropathy. Read More ›

Myocardial involvement was more common and distinct in male patients with variant transthyretin amyloidosis. Read More ›

To accurately diagnose and appropriately manage ATTRv, clinicians need to be aware of red-flag symptoms and recognize the critical value of genetic testing. Read More ›

It is essential for clinicians to recognize “red flag” symptoms to diagnose hATTR amyloidosis. Read More ›

Plasma biomarkers may help differentiate TTR V142I carriers from noncarriers in young preclinical cases. Read More ›

The T60A variant of hATTR presents with a high prevalence of neurologic manifestations that are more frequent at an earlier stage than cardiac manifestations. Read More ›